Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema

被引:2
作者
Riedl, Marc A. [1 ,4 ]
Bordone, Laura [2 ]
Revenko, Alexey [2 ]
Newman, Kenneth B. [2 ]
Cohn, Danny M. [3 ]
机构
[1] Univ Calif San Diego, Div Allergy & Immunol, La Jolla, CA USA
[2] Ionis Pharmaceut, Carlsbad, CA USA
[3] Univ Amsterdam, Dept Vasc Med, Amsterdam Cardiovasc Sci, Amsterdam UMC, Amsterdam, Netherlands
[4] Univ Calif San Diego, Div Allergy & Immunol, 8899 Univ Ctr Ln,Ste 230, San Diego, CA 92122 USA
关键词
ASO; Hereditary angioedema; Liver; Antisense oligonucleotide; siRNA; Gene therapy; CRISPR/Cas systems; PLASMA KALLIKREIN INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; GENE-THERAPY; CHALLENGES; MANAGEMENT; UPDATE; LIVER; HAE;
D O I
10.1016/j.jaip.2023.12.025
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Hereditary angioedema (HAE) is typically caused by a deficiency of the protease inhibitor C1 inhibitor (C1INH). The absence of C1INH activity on plasma kallikrein and factor XIIa leads to overproduction of the vasoactive peptide bradykinin, with resulting angioedema. As the primary site of C1INH and prekallikrein production, the liver is recognized as an important therapeutic target in HAE, leading to the development of hepaticfocused treatment strategies such as GalNAc-conjugated antisense technology and gene modification. This report reviews currently available data on hepatic-focused interventions for HAE that have advanced into human trials. Donidalorsen is an investigational GalNAc3-conjugated antisense oligonucleotide that binds to prekallikrein mRNA in the liver and reduces the expression of prekallikrein. Phase 2 data with subcutaneous donidalorsen demonstrated a significant reduction in HAE attack rate compared with placebo. Phase 3 trials are underway. ADX-324 is a GalNAc3-conjugated short-interfering RNA being investigated in HAE. BMN 331 is an investigational AAV5-based gene therapy vector that expresses wild-type human C1INH and is targeted to hepatocytes. A single intravenous dose of BMN 331 is intended to replace the defective SERPING1 gene and enable patients to produce functional C1INH. A first-in-human phase 1/2 study is ongoing with BMN 331. NTLA-2002 is an investigational in vivo clustered regularly interspaced short palindromic repeats/Cas9based therapy designed to knock out the prekallikrein-coding KLKB1 gene in hepatocytes; a phase 1/2 study is ongoing. Findings from these and other ongoing studies are highly anticipated with the expectation of expanding the array of treatment options in HAE. (c) 2024 American Academy of Allergy, Asthma & Immunology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/ oligonucleotide; siRNA; Gene therapy; CRISPR/Cas systems
引用
收藏
页码:911 / 918
页数:8
相关论文
共 63 条
  • [1] Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience
    Abuzakouk, Mohamed
    Ghorab, Omar
    Al-Hameli, Hamad
    Salvo, Fulvio
    Grandon, Deepa
    Maurer, Marcus
    [J]. WORLD ALLERGY ORGANIZATION JOURNAL, 2022, 15 (07):
  • [2] Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial
    Adams, David
    Tournev, Ivailo L.
    Taylor, Mark S.
    Coelho, Teresa
    Plante-Bordeneuve, Violaine
    Berk, John L.
    Gonzalez-Duarte, Alejandra
    Gillmore, Julian D.
    Low, Soon-Chai
    Sekijima, Yoshiki
    Obici, Laura
    Chen, Chongshu
    Badri, Prajakta
    Arum, Seth M.
    Vest, John
    Polydefkis, Michael
    [J]. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2023, 30 (01): : 18 - 26
  • [3] Al Rawahi Y, 2021, JPGN Rep, V2, P091
  • [4] Hereditary Angioedema as a Metabolic Liver Disorder: Novel therapeutic Options and Prospects for cure
    Ameratunga, Rohan
    Bartlett, Adam
    McCall, John
    Steele, Richard
    Woon, See-Tarn
    Katelaris, Constance H.
    [J]. FRONTIERS IN IMMUNOLOGY, 2016, 7
  • [5] [Anonymous], 2022, Cinryze [summary of product characteristics].
  • [6] [Anonymous], 2017, Business Wire
  • [7] [Anonymous], 2022, Haegarda
  • [8] [Anonymous], 2022, Orladeyo
  • [9] [Anonymous], 2022, Takhzyro
  • [10] Gene therapy clinical trials, where do we go? An overview
    Arabi, Fatemeh
    Mansouri, Vahid
    Ahmadbeigi, Naser
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2022, 153